Abstract
Galectins form a family of carbohydrate-binding proteins defined by their affinity for β-galactosides containing glycoconjugates. The carbohydrate recognition domain (CRD) is responsible for the specificity of galectins for saccharides. This binding may result in modulated cell proliferation, cell death and cell migration, three processes that are intimately involved in cancer initiation and progression. Galectins can also display protein-protein types of interactions with their binding partners. Certain galectins directly involved in cancer progression seem to be promising targets for the development of novel therapeutic strategies to combat cancer. Indeed, migrating cancer cells resistant to apoptosis still constitute the principal target for the cytotoxic drugs used to treat cancer patients. Reducing the levels of migration in apoptosis-resistant cancer cells can restore certain levels of sensitivity to apoptosis (and so to pro-apoptotic drugs) in restrictedmigration cancer cells. Anti-galectin agents can restrict the levels of migration of several types of cancer cell and should therefore be used in association with cytotoxic drugs to combat metastatic cancer. We provide experimental proof in support of this concept. While the present review focuses on various experimental strategies to impair cancer progression by targeting certain types of galectins, it pays particular attention to glioblastomas, which constitute the ultimate level of malignancy in primary brain tumors. Glioblastomas form the most common type of malignant brain tumor in children and adults, and no glioblastoma patient has been cured to date.
Keywords: Glioblastomas, Galectin-1 expression, Head and neck squamous cell carcinomas (HNSCC), Glycodendrimers, Modified Citrus Pectin (MCP)
Current Medicinal Chemistry
Title: Anti-Galectin Compounds as Potential Anti-Cancer Drugs
Volume: 13 Issue: 29
Author(s): Laurent Ingrassia, Isabelle Camby, Florence Lefranc, Veronique Mathieu, Prosper Nshimyumukiza, Francis Darro and Robert Kiss
Affiliation:
Keywords: Glioblastomas, Galectin-1 expression, Head and neck squamous cell carcinomas (HNSCC), Glycodendrimers, Modified Citrus Pectin (MCP)
Abstract: Galectins form a family of carbohydrate-binding proteins defined by their affinity for β-galactosides containing glycoconjugates. The carbohydrate recognition domain (CRD) is responsible for the specificity of galectins for saccharides. This binding may result in modulated cell proliferation, cell death and cell migration, three processes that are intimately involved in cancer initiation and progression. Galectins can also display protein-protein types of interactions with their binding partners. Certain galectins directly involved in cancer progression seem to be promising targets for the development of novel therapeutic strategies to combat cancer. Indeed, migrating cancer cells resistant to apoptosis still constitute the principal target for the cytotoxic drugs used to treat cancer patients. Reducing the levels of migration in apoptosis-resistant cancer cells can restore certain levels of sensitivity to apoptosis (and so to pro-apoptotic drugs) in restrictedmigration cancer cells. Anti-galectin agents can restrict the levels of migration of several types of cancer cell and should therefore be used in association with cytotoxic drugs to combat metastatic cancer. We provide experimental proof in support of this concept. While the present review focuses on various experimental strategies to impair cancer progression by targeting certain types of galectins, it pays particular attention to glioblastomas, which constitute the ultimate level of malignancy in primary brain tumors. Glioblastomas form the most common type of malignant brain tumor in children and adults, and no glioblastoma patient has been cured to date.
Export Options
About this article
Cite this article as:
Ingrassia Laurent, Camby Isabelle, Lefranc Florence, Mathieu Veronique, Nshimyumukiza Prosper, Darro Francis and Kiss Robert, Anti-Galectin Compounds as Potential Anti-Cancer Drugs, Current Medicinal Chemistry 2006; 13 (29) . https://dx.doi.org/10.2174/092986706779026219
DOI https://dx.doi.org/10.2174/092986706779026219 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomics in Computer-Aided Drug Design
Current Computer-Aided Drug Design Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Can Colorectal Cancer be Prevented or Treated by Oral Hormone Replacement Therapy?
Current Molecular Pharmacology Signaling Pathways Underpinning the Manifestations of Ionizing Radiation-Induced Bystander Effects
Current Molecular Pharmacology Methodological Issues of Clinical Research with EGFR Inhibitors
Current Cancer Therapy Reviews Theranostics Based on Iron Oxide and Gold Nanoparticles for Imaging- Guided Photothermal and Photodynamic Therapy of Cancer
Current Topics in Medicinal Chemistry Rational Drug Design of G-Quartet DNA as Anti-Cancer Agents
Current Pharmaceutical Design Evaluation of High Risk HPV (HPV-16 and -18) RNA and Integration in Cervical Neoplasms in Systemic Lupus Erythematosus
Current Women`s Health Reviews Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma
Current Cancer Drug Targets The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress
Current Molecular Medicine Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Lycopene Modulation of Molecular Targets Affected by Smoking Exposure
Current Cancer Drug Targets The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice
Current Genomics Procathepsin D as a Tumor Marker, Anti-Cancer Drug or Screening Agent
Anti-Cancer Agents in Medicinal Chemistry Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Combined Modality Therapy for Locally Advanced Head and Neck Cancer
Current Cancer Drug Targets Nuclear Factor Kappa B: A Potential Target to Persecute Head and Neck Cancer
Current Drug Targets Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Cytotoxic Activities of Difluoro-Dimethoxy Chalcones
Anti-Cancer Agents in Medicinal Chemistry